C75.8 Malignant neoplasm with pluriglandular involvement, unspecified

Name of the Condition

• Malignant neoplasm with pluriglandular involvement, unspecified
• ICD-10 Code: C75.8

Summary

Malignant neoplasm with pluriglandular involvement, unspecified, refers to cancerous growths affecting multiple endocrine glands or related structures without specifying the exact glands involved. These malignancies can disrupt hormonal regulation and systemic function, leading to varied clinical presentations. The condition is rare and may involve glands such as the parathyroid, pituitary, or adrenal, among others.

Causes

The development of this malignancy involves genetic mutations that cause uncontrolled cell growth in endocrine tissues. Contributing factors may include inherited genetic syndromes, environmental exposures, or sporadic mutations. The exact triggers vary depending on the specific glands affected.

Risk Factors

• Genetic syndromes (e.g., Multiple Endocrine Neoplasia)
• Radiation exposure to endocrine areas
• Age (risk increases with age)
• Family history of endocrine or related cancers
• Prior history of endocrine disorders

Symptoms

• Unexplained weight changes
• Fatigue or weakness
• Hormonal imbalances (e.g., electrolyte disturbances, blood pressure changes)
• Pain or swelling in affected glandular regions
• Visible lumps or masses in neck, abdomen, or other areas

Diagnosis

Diagnosis typically involves imaging studies (e.g., CT, MRI) to identify abnormal glandular growths, blood tests to assess hormonal levels and markers, and biopsy to confirm malignancy. Clinical evaluation focuses on identifying involvement of multiple glands and ruling out other conditions.

Treatment Options

Treatment may include surgery to remove affected glands, radiation therapy, chemotherapy, or targeted therapies. Hormonal management and supportive care are often necessary to address systemic effects. The approach depends on the extent of involvement and patient-specific factors.

Prognosis and Follow-Up

Prognosis varies based on the glands involved, stage of disease, and response to treatment. Regular follow-up with imaging, blood tests, and clinical assessments is essential to monitor for recurrence or progression. Long-term management may involve hormonal replacement or surveillance.

Complications

• Severe hormonal imbalances
• Metastasis to other organs
• Organ dysfunction due to glandular involvement
• Treatment-related side effects (e.g., radiation toxicity, surgical complications)

Lifestyle & Prevention

• Avoid known environmental carcinogens
• Maintain regular health screenings, especially with a family history of endocrine cancers
• Follow recommended guidelines for radiation exposure
• Manage underlying conditions that may increase risk

When to Seek Professional Help

Seek medical attention for persistent symptoms such as unexplained weight changes, fatigue, hormonal imbalances, or visible lumps. Prompt evaluation is critical if symptoms worsen or new issues arise.

Tips for Medical Coders

Document the specific glands involved when possible to support coding accuracy. Use C75.8 when pluriglandular involvement is confirmed but not specified. Ensure clinical documentation aligns with the diagnosis to justify code selection.